CD19 CAR-T therapy and sepsis: Dancing with the devil

Abstract

In this issue of Blood, Hill and colleagues characterized infectious complications in patients with relapsed or refractory B-cell malignancies after treatment with CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells in a phase 1/2 study.1 This is the first study that systemically analyzed infectious events in CAR-T-cell-treated patients.